The problem with the PSCI, the post-stroke cognitive impairment, is that the standardization of these outcomes is not very homogeneous throughout the studies. We need more collaborations, I guess, for defining these outcomes and also the biomarkers and when to measure the biomarker. There have been plenty of studies investigating imaging markers. These are quite ahead, so to speak. However, blood-based biomarkers are also promising but need to be validated in the future before they could be implemented in clinical routine...
The problem with the PSCI, the post-stroke cognitive impairment, is that the standardization of these outcomes is not very homogeneous throughout the studies. We need more collaborations, I guess, for defining these outcomes and also the biomarkers and when to measure the biomarker. There have been plenty of studies investigating imaging markers. These are quite ahead, so to speak. However, blood-based biomarkers are also promising but need to be validated in the future before they could be implemented in clinical routine. But as for the recurrent events, collaboration is key, I guess, and we need more broader and homogeneous data to answer these questions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.